8W0Q image
Deposition Date 2024-02-14
Release Date 2024-07-03
Last Version Date 2024-07-31
Entry Detail
PDB ID:
8W0Q
Keywords:
Title:
Pembrolizumab CDR-H3 Loop Mimic
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Conformers Calculated:
53799
Conformers Submitted:
20
Selection Criteria:
back calculated data agree with experimental NOESY spectrum
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Pembrolizumab CDR-H3 Loop Mimic
Chain IDs:A
Chain Length:20
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
De Novo Synthesis and Structural Elucidation of CDR-H3 Loop Mimics.
Acs Chem.Biol. 19 1583 1592 (2024)
PMID: 38916527 DOI: 10.1021/acschembio.4c00236

Abstact

The binding affinity of antibodies to specific antigens stems from a remarkably broad repertoire of hypervariable loops known as complementarity-determining regions (CDRs). While recognizing the pivotal role of the heavy-chain 3 CDRs (CDR-H3s) in maximizing antibody-antigen affinity and specificity, the key structural determinants responsible for their adaptability to diverse loop sequences, lengths, and noncanonical structures are hitherto unknown. To address this question, we achieved a de novo synthesis of bulged CDR-H3 mimics excised from their full antibody context. CD and NMR data revealed that these stable standalone β-hairpin scaffolds are well-folded and retain many of the native bulge CDR-H3 features in water. In particular, the tryptophan residue, highly conserved across CDR-H3 sequences, was found to extend the kinked base of these β-bulges through a combination of stabilizing intramolecular hydrogen bond and CH/π interaction. The structural ensemble consistent with our NMR observations exposed the dynamic nature of residues at the base of the loop, suggesting that β-bulges act as molecular hinges connecting the rigid stem to the more flexible loops of CDR-H3s. We anticipate that this deeper structural understanding of CDR-H3s will lay the foundation to inform the design of antibody drugs broadly and engineer novel CDR-H3 peptide scaffolds as therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures